Identification and Characterization of DNA-Oxaliplatin Adducts through α-hemolysin Nanopores

被引:4
作者
Li, Ting [1 ]
Lu, Wei [3 ]
Tian, Hui [1 ]
Cao, Yu [1 ,3 ]
He, Qianqian [1 ]
Chen, Xia [1 ,2 ]
Wang, Hailong [2 ]
机构
[1] Mianyang Normal Univ, Coll Life Sci & Biotechnol, Mianyang 621000, Peoples R China
[2] China Acad Engn Phys, Inst Nucl Phys & Chem, Mianyang 621000, Peoples R China
[3] Sichuan Univ, Coll Chem, Key Lab Green Chem & Technol, Minist Educ, Chengdu 610064, Peoples R China
基金
中国国家自然科学基金;
关键词
ALPHA-HEMOLYSIN; CISPLATIN; FLUOROURACIL; COMPLEXES; BINDING; DRUGS;
D O I
10.1021/acs.analchem.3c00461
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
The antitumor effect of Pt-based drugs is determinedby their bindingactivity with deoxyribonucleic acid (DNA), and understanding the reactionprocess in a systematic manner is crucial. However, existing assaysused for DNA-Pt research suffer from several issues, such ascomplicated sample preparation, preamplification, and expensive instruments,which dramatically limit their practical application. In this study,a novel method was presented to investigate the adducts of DNA andoxaliplatin using an & alpha;-hemolysin nanopore sensor. This approachallows for real-time monitoring of the DNA-oxaliplatin condensationprocess through the detection of nanopore events associated with DNA-oxaliplatinadducts. Specifically, type I and II signals exhibiting specific currentcharacteristics were observed during the process. Typical signalswith high frequency were obtained by recording the designed DNA sequence.Furthermore, the production of these signals was confirmed to be independentof homologous adducts. This finding suggests that the DNA-oxaliplatinadduct can serve as a potential sensor for detecting oxaliplatin lesionsand multiple types of molecules.
引用
收藏
页码:11201 / 11210
页数:10
相关论文
共 35 条
[1]   The discovery and development of cisplatin [J].
Alderden, RA ;
Hall, MD ;
Hambley, TW .
JOURNAL OF CHEMICAL EDUCATION, 2006, 83 (05) :728-734
[2]   Oxaliplatin (L-OHP): a new reality in colorectal cancer [J].
Bleiberg, H .
BRITISH JOURNAL OF CANCER, 1998, 77 (Suppl 4) :1-3
[3]   DNA-cisplatin binding mechanism peculiarities studied with single molecule stretching experiments [J].
Crisafuli, F. A. P. ;
Cesconetto, E. C. ;
Ramos, E. B. ;
Rocha, M. S. .
APPLIED PHYSICS LETTERS, 2012, 100 (08)
[4]   Cisplatin in cancer therapy: Molecular mechanisms of action [J].
Dasari, Shaloam ;
Tchounwou, Paul Bernard .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2014, 740 :364-378
[5]   Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].
de Gramont, A ;
Figer, A ;
Seymour, M ;
Homerin, M ;
Hmissi, A ;
Cassidy, J ;
Boni, C ;
Cortes-Funes, H ;
Cervantes, A ;
Freyer, G ;
Papamichael, D ;
Le Bail, N ;
Louvet, C ;
Hendler, D ;
de Braud, F ;
Wilson, C ;
Morvan, F ;
Bonetti, A .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947
[6]   Cellular and molecular aspects of drugs of the future: oxaliplatin [J].
Di Francesco, AM ;
Ruggiero, A ;
Riccardi, R .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2002, 59 (11) :1914-1927
[7]   Thermodynamics of Translesion Synthesis across a Major DNA Adduct of Antitumor Oxaliplatin: Differential Scanning Calorimetric Study [J].
Florian, Jakub ;
Brabec, Viktor .
CHEMISTRY-A EUROPEAN JOURNAL, 2012, 18 (06) :1634-1639
[8]   Update of the preclinical situation of anticancer platinum complexes: Novel design strategies and innovative analytical approaches [J].
Galanski, M ;
Jakupec, MA ;
Keppler, BK .
CURRENT MEDICINAL CHEMISTRY, 2005, 12 (18) :2075-2094
[9]   Analysis of cytotoxicities of platinum compounds [J].
Goodisman, J ;
Hagrman, D ;
Tacka, KA ;
Souid, AK .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (02) :257-267
[10]   A review of oxaliplatin and its clinical use in colorectal cancer [J].
Grothey, A ;
Goldberg, RM .
EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (10) :2159-2170